We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
WuXi PharmaTech Completes Construction of New Biosafety Testing Facility
News

WuXi PharmaTech Completes Construction of New Biosafety Testing Facility

WuXi PharmaTech Completes Construction of New Biosafety Testing Facility
News

WuXi PharmaTech Completes Construction of New Biosafety Testing Facility

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "WuXi PharmaTech Completes Construction of New Biosafety Testing Facility"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The facility consists of 38,000 square feet of laboratories and support areas in a building adjacent to WuXi's GLP preclinical drug safety facility. Operations will begin after validations are completed this summer. Service offerings will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for Chinese and multinational customers.

The new services will expand WuXi's already broad, integrated platform of biologics services. In the United States, WuXi offers biosafety testing services such as viral clearance validation and lot release and stability testing. In China, the company's services include novel monoclonal antibody discovery, discovery biology, drug screening, cell-line engineering and construction, toxicology, bioanalytical services, assay development, formulation, process development, and cGMP drug-substance and drug-product manufacturing for clinical trials.

"WuXi's expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "By investing in capabilities that address our customers' needs, we have become a leading biologics solution provider."


Advertisement